Shire, Barr In Talks To Settle Aderall XR Patent Challenge

Law360, New York (August 19, 2005, 12:00 AM EDT) -- U.K. drug maker Shire Pharmaceuticals is in talks with Barr Laboratories to try to settle out of court a patent challenge to Shire’s blockbuster hyperactivity drug Adderall XR.

The two companies initially refused to comment on rumors that they had struck a deal, but Shire was forced to make a statement on Friday after its stock prise rose markedly.

The two companies are involved in litigation concerning Barr's efforts to market a generic version of Shire's Adderall XR prior to the expiration of the Shire patents,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.